您当前的位置:
首页 >
文章列表页 >
Cost-effectiveness analysis of toripalimab combined with paclitaxel in the treatment of metastatic or recurrent triple-negative breast cancer
更新时间:2025-02-10
    • Cost-effectiveness analysis of toripalimab combined with paclitaxel in the treatment of metastatic or recurrent triple-negative breast cancer

    • ZHONGGUO YAOFANG   Vol. 36, Issue 3, Pages: 336-340(2025)
    • DOI:10.6039/j.issn.1001-0408.2025.03.13    

      CLC: R956;R979.1
    • Published:15 February 2025

      Received:17 July 2024

      Revised:08 January 2025

      Accepted:2025-01-10

    移动端阅览

  • YAN Wenying,TAO Xinyue,FENG Bing.Cost-effectiveness analysis of toripalimab combined with paclitaxel in the treatment of metastatic or recurrent triple-negative breast cancer[J].ZHONGGUO YAOFANG,2025,36(03):336-340. DOI: 10.6039/j.issn.1001-0408.2025.03.13.

  •  
  •  

0

Views

0

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

Cost-effectiveness analysis of ferric carboxymaltose for treating iron deficiency anemia in adult Chinese patients
Cost-utility analysis of sintilimab combined with chemotherapy in first-line treatment of advanced or recurrent non-small cell lung cancer
Cost-utility Analysis of Pembrolizumab in the Second-line Treatment of Advanced Hepatocellular Carcinoma Based on Two Models
Application of Different Decision Analysis Models in the Economic Evaluation of Antitumor Drugs :Taking CADTH in Canada as an Example

Related Author

MA Aixia
ZHUANG Lingxiang
SUN Wentao
HOU Yanhong
WU Fang
JIA Linlin
HU Mengxue
GAO Hongting

Related Institution

School of International Pharmaceutical Business,China Pharmaceutical University
Vifor Fresenius Kabi (Beijing) Pharmaceutical Consulting Co. Ltd.
Dept. of Epidemiology and Global Health, Umeå University, Umeå
0